InMed Pharmaceuticals Inc (TO:IN) is a Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Through its biosynthesis platform, the company believes it has distinct advantages over both naturally sourced and chemically synthesized cannabinoids, which could give it access to both the medical and retail markets, although the process is still in development. The company is also developing a proprietary pipeline, including INM-750 for epidermolysis bullosa (EB), a serious orphan indication, and expects to file an IND for INM-750 in H219.
InMed’s biosynthesis platform may have advantages
InMed’s E. coli bacteria-based biosynthesis platform may have some distinct advantages over currently used methods, according to management. It may be faster and provide a better-controlled and purer product than extraction from plants and chemical synthesis, and provide a cost-efficient way to manufacture over 90 minor cannabinoids that have different properties than tetrahydrocannabinol (THC) and cannabidiol (CBD). However, the process is still under development and is undergoing optimization and commercial scale-up.
To read the entire report Please click on the pdf File Below: